Predictors of Outcome after Alcohol Septal Ablation Therapy in Patients with Hypertrophic Obstructive Cardiomyopathy

Su-Min Chang, Nasser M. Lakkis, Jennifer Franklin, William H. Spencer, Sherif Nagueh

Research output: Contribution to journalArticlepeer-review

99 Scopus citations


Background-Alcohol septal ablation (ASA) therapy results in clinical and hemodynamic improvement in patients with hypertrophic obstructive cardiomyopathy. However, a subset remains symptomatic afterward, requiring additional procedures. We sought to examine the determinants of an unsatisfactory outcome, defined as unchanged symptoms with <50% reduction of baseline left ventricular outflow tract (LVOT) gradient. Methods and Results-Of 173 consecutive hypertrophic obstructive cardiomyopathy patients who underwent ASA, 39 had an unsatisfactory outcome after the first procedure. Patients with an unsatisfactory outcome had a higher baseline LVOT gradient, fewer septal arteries injected with ethanol, lower peak creatine kinase (CK), smaller septal area opacified by contrast echocardiography, and higher residual gradient in the catheterization laboratory after ASA (all P<0.05). Symptoms, septal thickness, mitral regurgitation severity, and ventricular function were not determinants of outcome. On multiple logistic regression, LVOT gradient reduction after ASA in the catheterization laboratory to ≥25 mm Hg (OR, 5.5; P=0.01) and peak CK <1300 U/L (OR, 2.5; P=0.04) were the independent predictors of an unsatisfactory outcome. Conclusions-The residual LVOT gradient in the catheterization laboratory and peak CK leak after ASA are the independent predictors of ASA outcome.

Original languageEnglish (US)
Pages (from-to)824-827
Number of pages4
Issue number7
StatePublished - Feb 24 2004


  • Ablation
  • Alcohol
  • Cardiomyopathy
  • Hypertrophy

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Predictors of Outcome after Alcohol Septal Ablation Therapy in Patients with Hypertrophic Obstructive Cardiomyopathy'. Together they form a unique fingerprint.

Cite this